Left ventricular assist devices (LVADs) have emerged as a mainstay, lifesaving treatment
option for patients with refractory heart failure, with 1-and 2-year actuarial survival rates of …

Background This study reports a single-center experience with thrombolytics for left
ventricular assist device (LVAD) pump thrombosis. Methods Adults undergoing continuous …

Left ventricular assist devices (LVAD) are an increasingly implemented therapeutic
intervention for patients with end-stage heart failure. A growing body of evidence, however …

Pump thrombosis is a dreaded complication of left ventricular assist devices (LVADs). We
completed a systematic review to evaluate the efficacy and complications associated with …

During the past several decades, left ventricular assist devices (LVADs) have become a
valuable therapeutic option in the management of advanced systolic heart failure. Durable …

Left ventricular assist devices (LVADs) are now a durable mainstay of therapy for medically
refractory advanced heart failure (HF). 1 Continuous-flow LVADs demonstrated increased …

Feature Editor's Introduction—Durable left ventricular assist device (LVAD) therapy has had
a remarkable evolution over the past 2 decades. Moving from a therapy once confined to …

The gradual evolution of left ventricular assist device (LVAD) therapy has resulted in a
durable option for patients as either a bridge to transplantation (BTT) or a destination …

The clinical community faces major issues in caring for the 100,000 to 300,000 advanced
heart failure patients in the United States. 1 For these patients, left ventricular assist devices …

Background Despite advances in pump technology, thromboembolic events/acute pump
thrombosis remain potentially life-threatening complications in patients with continuous-flow …